Neurology® Podcast

1) Systematic review and statistical analysis of the integrity of 33 randomized controlled trials2) What's Trending: Interview with Dr. Neil Garrett about his Nature Neuroscience article on dishonesty.3) Topic of the month: Neurology Today story about Zika virus and Guillain Barre syndrome detected in ColumbiaThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Mark Bolland about his paper on the systematic review and statistical analysis of the integrity of 33 randomized controlled trials. Dr. Ted Burns is also interviewing Dr. Neil Garrett for our “What's Trending” feature of the week about his Nature Neuroscience paper on dishonesty. In the next part of the podcast Dr. Ted Burns interviews Dr. Carlos Pardo about a Neurology Today story on the topic of Zika virus and Guillain Barre syndrome detected in Columbia.DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Bolland receives research support from the Health Research Council of New Zealand.Dr. Pardo receives research support from Bart McLean Fund for Neuroimmunology Research-Project Restore and the NIH.All other participants report no disclosures.

Join Thomas Bird, an expert in human germline editing, and John Hardy, a groundbreaking researcher in Alzheimer’s genetics, as they dive into the fascinating world of neurogenetics. They discuss the latest advancements in sequencing technologies, the complexities of deciphering genetic inheritance in neurological conditions, and the ethical implications of CRISPR technology. Hardy shares insights from his research on Alzheimer's genes, while Bird emphasizes the urgent need for improved genetic counseling. Together, they navigate the future of genetic research and its transformative impact on healthcare.

1) Practice advisory: The utility of EEG theta/beta power ration in ADHD diagnosis2) e-Pearl topic: Hemiplegic migraine3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Adam Numis interviews Dr. David Gloss about this AAN Practice Advisory paper on the utility of EEG theta and beta power ration in attention deficit hyperactivity disorder diagnosis. Dr. Ilena George is reading our e-Pearl of the week about hemiplegic migraine. In the next part of the podcast Dr. Alberto Espay interviews Dr. Steven Frucht on the topic of “how to approach” myoclonus.DISCLOSURES: Dr. Numis served on the editorial team for the Neurology® Resident and Fellow Section. Dr. Gloss serves on the Level of evidence team for Neurology®; is an Evidence-based medicine consultant for the American Academy of Neurology; receives royalties from the publication of the book Neurology for the Specialty Boards.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Frucht serves as Editor-in-Chief for the Journal of Clinical Movement Disorders; is a consultant for UCB; received speaker honoraria from Merz Pharmaceuticals, LLC and Impax; receives royalties from the publication of the book Movement Disorders Emergencies; and is employed by the American Academy of Neurology Movement Disorders Society.

1) Emerging temporal trends in tissue plasminogen activator use: Results from the BASIC project2) e-Pearl topic: Transthyretin familial amyloid polyneuropathy3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Lynda Lisabeth about her paper on temporal trends in tissue plasminogen activator administration for acute ischemic stroke. Dr. Ilena George is reading our e-Pearl of the week about transthyretin familial amyloid polyneuropathy. In the next part of the podcast Dr. Jeff Ratliff interviews Dr. Ruth Walker on the topic of chorea.DISCLOSURES: Dr. Barrett serves as Associate Editor for Neurohospitalist; serves as an editorial board member for Neurology®; receives royalties from the publication of the book Stroke and editing the book Neurology in Practice; and receives research support from the NIH.Dr. Lisabeth receives research support from the NIH.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Walker is a consultant for Neurocrine Biosciences, Inc.; assists with Audio-Digest Board Reviews; received funding for travel from Korean Movement Disorders Society and honoraria from Neurocrine Biosciences, Inc.

1) Efficacy and safety of deflazacort versus prednisone and placebo for Duchenne muscular dystrophy2) e-Pearl topic: Alien limb phenomenon3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kelly Gwathmey interviews Dr. Robert Griggs about his the efficacy and safety of deflazacort versus prednisone for boys with Duchenne muscular dystrophy. Dr. Ilena George is reading our e-Pearl of the week about alien limb phenomenon. In the next part of the podcast Dr. Alberto Espay interviews Dr. Don Gilbert on the topic of tics.DISCLOSURES: Dr. Griggs serves as Correspondence Editor for Neurology®; serves as an editorial board member of NeuroTherapeutics and Current Treatment Opinions in Neurology; serves on the scientific advisory board for SAB for National Hospital Queen Square, Marathon Pharmaceuticals, PTC Therapeutics, Inc., DSMB, Taro Pharm and Sarepta Pharmaceuticals; is a consultant for Marathon, PTC Therapeutics, Sarepta, Taro Pharm and Idera Pharmaceuticals;receives royalties for data of previous studies from Taro Pharm and Marathon Pharmaceuticals; receives royalties from the publication of the books: Andreoli and Carpenter's Cecil Essentials of Medicine, Eighth Edition, Cecil Textbook of Medicine, multiple editions and Evaluation and Treatment of Myopathies; receives research support from Taro Pharma, Marathon Pharmaceuticals, Parent Project Muscular Dystrophy, Inc., Muscular Dystrophy Association, Novel Molecular Mechanisms of Neuromuscular Disease: Implications for Therapy and the NIH.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Gilbert serves on the scientific advisory boards of Investigations of Neuroplasticity Mechanisms in Autism Spectrum Disorders, the Berenson-Allen Center for Noninvasive Brain Stimulation, and Beth Israel Deaconess Medical Center; received honoraria from the Tourette Association of America, the Centers for Disease Control and Prevention, and the Hong Kong Society of Child Neurology and Developmental Pediatrics; received funding for travel for educational talks to physicians and affected patients and families;receives royalties from the publication of the book Movement Disorders in Childhood, 2nd edition; receives research support from Ecopipam Pharmaceuticals, Neurocrine Pharmaceuticals, EryDel Pharmaceuticals, and NIH; and has provided expert testimony for the Health Resources and Services Administration, Department of Health and Human Services regarding Division of Vaccine Injury Compensation Programs.

1) Progression of brain atrophy in PSP and CBS over six months and one year2) What's Trending: Interview with Mike Amery about Medicare Sustainable Growth Rate repeal and the Medicare Access and CHIP Reauthorization Act 3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Morgan interviews Dr. Adam Boxer about his paper about on progression of brain atrophy in progressive supranuclear palsy and corticobasal syndrome. Dr. Ted Burns is interviewing Mike Amery for our “What's Trending” feature of the week about Medicare Sustainable Growth Rate repeal and the Medicare Access and CHIP Reauthorization Act. In the next part of the podcast Dr. Alberto Espay interviews Dr. Rodger Elble on the topic of “how to approach” tremor disorders.DISCLOSURES: Dr. Morgan is a consultant for Impax, Lundbeck Inc., National Parkinson Foundation, Teva Pharmaceutical Industries Ltd., and Veloxis; serves on the speakers' bureau of Impax and Teva Pharmaceutical Industries Ltd.; received compensation for review of medical records and expert witness testimony in multiple cases of litigation involving neurologic co; receives research support from National Parkinson Foundation, Parkinson's Outcome Project Grant and the NIH.Dr. Boxer serves on the scientific advisory board for Alector, Asceneuron and Delos; received funding for travel from the International Society for CNS Clinical Trials Methodology, the Movement Disorders Society, the Association for Frontotemporal Degeneration, Fidelity Biosciences Research Institute and the Tau Consortium; is a consultant for Abbvie, Ionis, Janssen and Merck Serono; holds stock options in Alector and Delos; receives research support from Avid, Biogen Idec, BMS, C2N, Cortice, Forum, Genentech, Inc., Janssen, Pfizer Inc, Eli Lilly and Company, Roche, TauRx, The Tau Research Consortium, the Bluefield Project, Corticobasal Degeneration Solutions, the Alzheimer's Association and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Amery is employed as Legislative Counsel for the American Academy of Neurology.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Elble receives research support from GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Phytopharm, Pfizer Inc, Ortho-McNeil, Spastic Paralysis Research Foundation of Kiwanis International, Illinois-Eastern Iowa District and the NIH.

Interviews from Neurology Today articles on the topic of stroke.

1) School aged cognition in children exposed to levetiracetam, topiramate or sodium valproate2) What's Trending: Interview with David Spencer about his book titled: “Navigating life with epilepsy” 3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. Rebecca Bromley about her paper about school aged cognition in children exposed to levetiracetam, topiramate or sodium valproate. Dr. Ted Burns is interviewing Dr. David Spencer for our “What's Trending” feature of the week about his recently published Neurology Now book titled: “Navigating life with epilepsy.” In the next part of the podcast Dr. Jeff Ratliff interviews Prof. Kailash Bhatia on the topic of “how to approach” dystonia.DISCLOSURES: Dr. Fountain is an epileptologist at the University of Virginia Comprehensive Epilepsy Program (100% effort).Dr. Bromley provided expert testimony regarding fetal valproate syndrome in the UK; although this case did not go to court and received research support from Epilepsy Research UK.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Spencer serves as Patient Page Editor for Neurology®, including past 2 years EMedicine, Chief Editor, Journal of Behavior and Brain Science, Associate Editor Neurology Now, Professional Advisory Board, including past 2 years Epilepsy Currents: Contributing editor; received honorariafrom NeuroPace Inc.; receives research support from NeuroPace, Inc., Upsher-Smith Laboratories, Inc., and Acorda; and was a consultant in a legal case. Prof. Bhatia serves as Co-Editor in Chief for Movement disorders Clinical Practice, serves as an Associate Editor for Movement Disorders, serves as an editorial board member of Therapeutic Advances in Neurological Disorders; received funding for travel from GlaxoSmithKline, Orion Corporation, Ipsen Pharmaceuticals, Inc., Merz Pharmaceuticals, LLC, Sun Pharmaceuticals Ltd, received honoraria from GlaxoSmithKline, Ipsen Pharmaceuticals, Inc., Merz Pharmaceuticals, LLC, Sun Pharmaceutical Industries Ltd.; is a consultant for Allergan, Inc., Ipsen Pharmaceuticals, Inc., MerzPharmaceuticals, LLC; receives royalties from the publication of Oxford Specialist Handbook of Parkinson's Disease and Other Movement Disorders, Marsdens book of Movement disorder, Lancet Neurology review article; receives research support from Wellcome Trust MRC strategic neurodegenerative disease initiative award, Parkinson's UK, Dystonia Coalition and The Bachmann-Strauss Foundation.

1) HIV associated motor neuron disease: HERV-K activation and response to anti-retroviral therapy 2) e-Pearl topic: Ataxia with vitamin E deficiency3) Topic of the month: Neurology Today story on functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional careThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Avindra Nath about his paper on human endogenous retrovirus-K in amyotrophic lateral sclerosis with HIV infection and response to treatment with anti-retroviral drugs. Dr. Sarah Wesley is reading our e-Pearl of the week about ataxia with vitamin E deficiency. In the next part of the podcast Dr. Andy Southerland interviews Prof. Heinrich Audebert about a Neurology Today story on the topic of functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional care.DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Nath serves as Associate Editor for Journal of Neurovirology; has patents for Tat as an immunogen, Diosgenin for Treatment of Neurodegenerative Diseases; Role of Kv Channels in Neuroregeneration and Protection; Role of Lominoid compounds as neuroprotective agents; Tat ELISA; and receives research support from the NIH.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Prof. Audebert serves as Associate Editor for Frontiers of Teleneurology; is a consultant for Lundbeck Inc., Roche, Bayer Schering Pharma, Pfizer Inc; received speaker honoraria from Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Lundbeck Inc., Bayer Schering Pharma, UCB, Sanofi-aventis, Pfizer Inc, Bristol-Myers Squibb and EverNeuropharma; participated in an expert meeting launched by Lundbeck Inc. in order to estimate the target population for Desmoteplase; receives research support from the Technology Foundation Berlin and the Berlin Investment Bank with co-financing by the European Union, and Center for Stroke Research Berlin, funded by the German Federal Ministry of Education and Research.

1) Calcium supplementation and risk of dementia in women with cerebrovascular disease2) e-Pearl topic: MGMT promoter methylation in glioblastoma3) Topic of the month: Neurology Today story on a new brain map identifying previously unidentified brain areas and what it means for neurologyThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Silke Kern about her paper on whether calcium supplementation was associated with the development of dementia in women with cerebrovascular disease. Dr. Sarah Wesley is reading our e-Pearl of the week about MGMT promoter methylation in glioblastoma. In the next part of the podcast Dr. Ted Burns interviews Dr. Matthew Glasser about a Neurology Today story on the topic about a new brain map identifying previously unidentified brain areas and what it means for neurology.DISCLOSURES: Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Kern serves as Associate Editor for Journal of Alzheimer`s disease.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.